Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis
about
The Current and Future Treatment of Brain MetastasesIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsThe role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaRoles of c-Met and RON kinases in tumor progression and their potential as therapeutic targetsBiology of MET: a double life between normal tissue repair and tumor progressionBrain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.Current approaches to the treatment of metastatic brain tumours.Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung CancerA comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistryExosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell linesAkt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.Identification of Caspase Cleavage Sites in KSHV Latency-Associated Nuclear Antigen and Their Effects on Caspase-Related Host Defense Responses.Molecular Markers with Predictive and Prognostic Relevance in Lung CancerComplexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?Tyrosine kinase inhibitors in lung cancer.Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer.Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibitionEGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.Targeting genomic alterations in squamous cell lung cancer.A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells.Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.MicroRNAs as therapeutic targets in chemoresistance.Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.MET: a promising anticancer therapeutic target.EGFR mutation status in brain metastases of non-small cell lung carcinoma.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.Molecular determinants of lung cancer metastasis to the central nervous system.cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.
P2860
Q26744019-EDA22BDA-AA2E-4DCC-8A2F-27EE5B21F058Q26744339-FC4EFE7A-F5C0-41E9-819A-17E74603643BQ26823903-75F8AE46-A52D-485A-B9B3-CABAF9BBC467Q26852215-87116743-0386-4E74-A127-FC95DCA69DCAQ27853202-A24E88E1-0542-4A18-9C6B-F888DF72BACBQ28081193-08A8DC8D-E481-4C02-9F16-6B731A4495A2Q28085247-5DA525BC-A8D5-4B3E-BEB5-B368F1CB469CQ33430404-9D81D896-46B9-400B-89A3-554F63E0C421Q33696559-E7B78EC2-9449-4044-A5E9-C8D36B984980Q33859503-6AE0ECCA-2B0B-4C61-87A5-52F88FF402A8Q34405695-6C7E54D2-FEFC-477E-8D0A-135CDBCF6D02Q35143602-900928CF-2E96-42BB-9199-939B37B93469Q35153559-9224D5DB-030F-41C4-88B3-94237260230CQ35195738-B5F0D24C-134D-4375-AB31-D99B912CFC48Q35208173-63DF6213-9051-433B-8EE1-1FC8FA419B2BQ35612939-8DDF66C2-0ECE-4D7D-86B0-7EFBDA95B978Q35636713-C1AA86F7-A5A1-40EF-A7F7-69FA13210243Q35720026-1B3EC45F-9DE2-4EF2-A982-C228A4D3D6ECQ35763239-2E620D1D-9618-4BC1-9983-419D91D3464FQ35882137-D947FDEA-7A96-4D56-A1B9-CBD1CE3B0B13Q35896530-700F344B-353C-4D07-9B4D-AF985C992635Q35908430-03009D05-B8DB-4D85-9932-6C5CA4AEF016Q36173303-8CBB6DD5-973C-4C15-99D7-A8C59A85574FQ36264188-7ABE9901-46DA-4A6E-AAFD-9E25DB556236Q36265149-326EFD37-A4A6-4DC5-A28D-FF7A394C9095Q36826056-DEA703C3-1CB1-4744-A57C-BD7C996A5F97Q36884275-6C197E8F-0CA8-4AAC-A993-A7AE08A090BDQ37068767-DD38737B-3EE0-46DE-9169-0231B08B70DCQ37109747-E75D1742-1EDF-4510-8664-1ECA8781F110Q37210782-6CD3152E-2186-4178-B65B-8CF093F28121Q37381107-0AB525B6-C289-4A70-A26A-F49E0A1F43CEQ37392703-14807521-ED45-4AED-B14A-F3E1B0622A3EQ37702041-E498A40D-43B2-459C-981D-A62113CC72F6Q37894095-EE208535-38F8-4F4B-8C32-C036420439B4Q38008247-BEFC93C2-EAB7-4044-8DA9-3A44388981C9Q38053963-5A67AD3E-EF08-49E9-9EF3-015355C10A9AQ38152999-2BCA74EC-6B1A-4523-BE8C-A8DE741C78A7Q38245669-F170F040-132A-4B17-BB23-6EFB773C4299Q38390049-A04A73A4-3770-4057-BC07-EF820068582FQ38393333-7588209B-4722-4300-A099-CD2450E15B7F
P2860
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Met activation in non-small ce ...... evelopment of brain metastasis
@ast
Met activation in non-small ce ...... evelopment of brain metastasis
@en
type
label
Met activation in non-small ce ...... evelopment of brain metastasis
@ast
Met activation in non-small ce ...... evelopment of brain metastasis
@en
prefLabel
Met activation in non-small ce ...... evelopment of brain metastasis
@ast
Met activation in non-small ce ...... evelopment of brain metastasis
@en
P2093
P2860
P1476
Met activation in non-small ce ...... evelopment of brain metastasis
@en
P2093
Adi F Gazdar
Azra H Ligon
Bart Lutterbach
Beow Y Yeap
Bo-Sheng Pan
Christopher Ware
Dyane Bailey
Elisa Benedettini
Giulio Draetta
John D Minna
P2860
P304
P356
10.2353/AJPATH.2010.090863
P407
P50
P577
2010-05-20T00:00:00Z